MARIE ASTRID PHARMA: what changed
MARIE ASTRID PHARMA
Largest movements
- Tangible fixed assets -€5,754
down €5,754 (-5.1%), from €113,665 to €107,911
of which Land and buildings: -€5,610
- Cash -€2,262
down €2,262 (-90.5%), from €2,499 to €237
mainly Debts after one year (-€8,182) and Receivables within one year (-€381)
- Debts after one year -€8,182
down €8,182 (-2.1%), from €390,805 to €382,623
- Gross operating margin -€375
down €375 (-4.5%), from €8,318 to €7,943
- Depreciation +€87
up €87 (+1.5%), from €5,667 to €5,754
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €117,657 | €110,022 | -€7,635 | -6.5% |
| Fixed assets | 21/28 | €113,665 | €107,911 | -€5,754 | -5.1% |
| Tangible fixed assets | 22/27 | €113,665 | €107,911 | -€5,754 | -5.1% |
| Land and buildings | 22 | €112,274 | €106,664 | -€5,610 | -5.0% |
| Other tangible fixed assets | 26 | €1,391 | €1,247 | -€144 | -10.4% |
| Current assets | 29/58 | €3,992 | €2,111 | -€1,881 | -47.1% |
| Amounts receivable within one year | 40/41 | €1,493 | €1,874 | +€381 | +25.5% |
| Trade receivables | 40 | €1,493 | €1,874 | +€381 | +25.5% |
| Cash at bank and in hand | 54/58 | €2,499 | €237 | -€2,262 | -90.5% |
| Total equity and liabilities | 10/49 | €117,657 | €110,022 | -€7,635 | -6.5% |
| Equity | 10/15 | -€274,759 | -€274,903 | -€144 | -0.1% |
| Contributions | 10/11 | €50,000 | €50,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€324,759 | -€324,903 | -€144 | 0.0% |
| Amounts payable | 17/49 | €392,416 | €384,925 | -€7,491 | -1.9% |
| Amounts payable after more than one year | 17 | €390,805 | €382,623 | -€8,182 | -2.1% |
| Other amounts payable | 178/9 | €390,805 | €382,623 | -€8,182 | -2.1% |
| Amounts payable within one year | 42/48 | €1,611 | €2,302 | +€691 | +42.9% |
| Trade debts | 44 | €1,595 | €2,286 | +€691 | +43.3% |
| Suppliers | 440/4 | €1,595 | €2,286 | +€691 | +43.3% |
| Taxes, remuneration and social security | 45 | €16 | €16 | = | 0.0% |
| Taxes | 450/3 | €16 | €16 | = | 0.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €5,667 | €5,754 | +€87 | +1.5% |
| Other operating charges | 640/8 | €2,205 | €2,274 | +€69 | +3.1% |
| Gross operating margin | 9900 | €8,318 | €7,943 | -€375 | -4.5% |
| Operating profit (loss) | 9901 | €446 | -€85 | -€531 | |
| Financial charges | 65/66B | €46 | €58 | +€12 | +26.1% |
| Recurring financial charges | 65 | €46 | €58 | +€12 | +26.1% |
| Profit (loss) for the period before taxes | 9903 | €400 | -€143 | -€543 | |
| Profit (loss) for the period | 9904 | €400 | -€143 | -€543 | |
| Profit (loss) for the period to be appropriated | 9905 | €400 | -€143 | -€543 |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 6 November 2026 via checked.be.